TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17380986

Group type: EXPERIMENTAL
Intervention: Comprehension program integrated with social studies instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Content-only program focusing on social studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-instruction control
Number of subjects: 0
Study: 15118484

Group type: COMPARATOR
Intervention: Abnormal Involuntary Movement Scale (AIMS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dyskinesia Identification Scale, Condensed User Version (DISCUS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Instrumental assessment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mini‐Mental Status Examination
Number of subjects: 100
Study: 11447543

Group type: EXPERIMENTAL
Intervention: Dilute epinephrine irrigation (0.33 mg/L)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo group (plain saline irrigation)
Number of subjects: 54
Study: 9497191

Group type: EXPERIMENTAL
Intervention: MM+MNF
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MM+CaGP
Number of subjects: 25

Group type: COMPARATOR
Intervention: PTF
Number of subjects: 25
Study: 8056798

Group type: EXPERIMENTAL
Intervention: RD heparin administered twice daily (50 anti-factor-Xa units/kg, subcutaneously, twice daily)
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: RD heparin administered once daily (90 anti-factor-Xa units/kg, subcutaneously, once daily)
Number of subjects: 969

Group type: COMPARATOR
Intervention: Warfarin (5 mg orally preoperatively, adjusted daily)
Number of subjects: 969
Study: 3052556

Group type: EXPERIMENTAL
Intervention: Nalbuphine 60 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nalbuphine 30 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dihydrocodeine 30 mg
Number of subjects: 75
Study: 31356514

Group type: EXPERIMENTAL
Intervention: 30‐second/4‐minute interval training protocol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1‐minute/1‐minute interval training protocol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 4‐minute/3‐minute interval training protocol
Number of subjects: 8

Group type: COMPARATOR
Intervention: 45‐minute continuous exercise session
Number of subjects: 8
Study: 31664298

Group type: EXPERIMENTAL
Intervention: R3 (Halitosil Zn) mouth rinse
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: R2 (Colgate plax) mouth rinse
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: R7 (Oxyfresh power mouth rinse lemon‐mint)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: R8 (Signal expert protection)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mouth rinses containing ZnCl2 without alcohol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mouth rinses containing ethyl and other alcohols
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Freshness effect
Number of subjects: 90
Study: 29354975

Group type: EXPERIMENTAL
Intervention: Acupuncture at distal acupoints (Guangming GB 37, Diwuhui GB 42)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture at local acupoints (Cuanzhu BL 2, Tongziliao GB 1, Taiyang EX-HN 5)
Number of subjects: 40
Study: 25906557

Group type: EXPERIMENTAL
Intervention: Opposing needling technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Affected side needling technique
Number of subjects: 40
Study: 24138325

Group type: EXPERIMENTAL
Intervention: Shared decision making programme
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control-intervention targeting nutrition, sports, and stress coping
Number of subjects: 154
Study: 21388622

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) supplement (300 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19016091

Group type: EXPERIMENTAL
Intervention: Clinician-assisted computerized cognitive behavioural treatment (CaCCBT)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Self-guided computerized CBT (CCBT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 98
Study: 16140281

Group type: EXPERIMENTAL
Intervention: Iomazenil
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: m-CPP
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Iomazenil and m-CPP
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12653682

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS) subjects
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Plasma campesterol:cholesterol ratio
Number of subjects: 35
Study: 10911512

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg and Ibuprofen 600 mg concomitantly
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg and Zaleplon 10 mg concomitantly
Number of subjects: 17
Study: 8612031

Group type: EXPERIMENTAL
Intervention: 30 min cycle ergometry at approximately 100 W (mean 98.8 W; range 34‐151 W)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 min cycle ergometry
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control day without exercise
Number of subjects: 11
Study: 1598509

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment at 6-month intervals for two years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment at 6-month intervals for two years
Number of subjects: 0
Study: 6427820

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) administered orally
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) administered intramuscularly
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) and its metabolites
Number of subjects: 4
Study: 29861827

Group type: EXPERIMENTAL
Intervention: 10 km time trial run at 18:00 hs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 km time trial run at 09:00 hs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Assessment of IL-6, HSP70, WBC, neutrophil, lymphocyte, and CC16 concentrations
Number of subjects: 13
Study: 27267588

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Depression Symptoms (DS)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control group (no depression symptoms)
Number of subjects: 430
Study: 25038355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: FTC+TDF
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: PrEP (TDF or FTC+TDF)
Number of subjects: 1785
Study: 22345429

Group type: EXPERIMENTAL
Intervention: Octreotide acetate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20339879

Group type: EXPERIMENTAL
Intervention: Landiolol infusion (0.125 mg/kg/min for 1 min, then 0.01‐0.04 mg/kg/min until 6 h after anesthesia)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Landiolol infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study: 18525385

Group type: EXPERIMENTAL
Intervention: Home-based intervention (INT) involving a diary of physical activities and quarterly group meetings
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard treatment (usual care)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Home-based intervention (INT)
Number of subjects: 228
Study: 15935231

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 147
Study: 12771001

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I/phosphatidylcholine (apoA-I/PC) disks infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline measurements in ABCA1 heterozygotes
Number of subjects: 18
Study: 10801996

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 8857615

Group type: EXPERIMENTAL
Intervention: 5F catheter (group BPH 1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10F filling catheter (group BPH 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (nonobstructed)
Number of subjects: 64
Study: 1514342

Group type: EXPERIMENTAL
Intervention: Alfentanil (12.5 micrograms/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam (20 micrograms/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regional anesthesia (with any premedication)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Premedication (any)
Number of subjects: 90
Study: 6329395

Group type: EXPERIMENTAL
Intervention: Misonidazole administered 4 to 5 hours before each fraction of radiotherapy (total of 11 to 13 g/m2)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo administered 4 to 5 hours before each fraction of radiotherapy
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 267
Study: 30230376

Group type: EXPERIMENTAL
Intervention: Assessment by orthodontists
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Assessment by radiologists
Number of subjects: 60
Study: 28324822

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery (MIS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 21
Study: 25592045

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23255688

Group type: EXPERIMENTAL
Intervention: 1mg/kg/day of elemental zinc
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 21310311

Group type: EXPERIMENTAL
Intervention: 150 mg/day clopidogrel
Number of subjects: 50

Group type: COMPARATOR
Intervention: 75 mg/day clopidogrel
Number of subjects: 50
Study: 19772583

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 638

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 638
Study: 17032099

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) plus contingency management (CM)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) without CM
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Individual drug counseling (DC) plus CM
Number of subjects: 136

Group type: COMPARATOR
Intervention: DC without CM
Number of subjects: 136
Study: 12775205

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment (20 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Undisturbed side lying (20 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Undisturbed side lying
Number of subjects: 10
Study: 11816733

Group type: EXPERIMENTAL
Intervention: Activelle (1 mg 17 beta‐estradiol combined with 0.5 mg norethisterone acetate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (20 women)
Number of subjects: 100
Study: 9196674

Group type: EXPERIMENTAL
Intervention: Monocular viewing conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Binocular but non-stereoscopic viewing conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normal binocular viewing conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Frisby stereotest (control)
Number of subjects: 16
Study: 7931881

Group type: EXPERIMENTAL
Intervention: Lipid emulsion supplemented with gamma-linolenic acid and long-chain triglycerides (LCT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 59

Group type: COMPARATOR
Intervention: 50% (wt/wt) mixture of medium-chain triglycerides and LCT emulsion
Number of subjects: 59
Study: 2887430

Group type: EXPERIMENTAL
Intervention: High-dose intravenous streptokinase (1.5 MU over one hour)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Oral aspirin (325 mg on alternate days for 28 days)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Intravenous heparin (1000 IU h‐1 for 48 hours)
Number of subjects: 619
Study: 29683078

Group type: EXPERIMENTAL
Intervention: Grand Theft Auto (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Madden NFL 12 (control group)
Number of subjects: 0
Study: 28708221

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) intravitreal implant
Number of subjects: 18
Study: 26396166

Group type: EXPERIMENTAL
Intervention: Client-centred, activities of daily living intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: Usual activities of daily living
Number of subjects: 183
Study: 25919281

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (common drugs only)
Number of subjects: 102
Study: 23463093

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (30 patients)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No adjuvant radiotherapy (83 patients)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (10 positive patients)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Overall recurrence (all patients)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Radiotherapy area recurrence (all patients)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: T status
Number of subjects: 113
Study: 22123359

Group type: EXPERIMENTAL
Intervention: Conivaptan
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Conivaptan and Furosemide
Number of subjects: 8
Study: 19447264

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment at L5 using manually assisted mechanical force (Activator)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment at L5 using traditional diversified technique spinal manipulation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham treatment in pain-free group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Treatment pain-free group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sham pain group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sham pain-free group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Treatment pain group
Number of subjects: 51
Study: 16931460

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 14
Study: 12921476

Group type: EXPERIMENTAL
Intervention: SLI381 10 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SLI381 20 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SLI381 30 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 51
Study: 11121915

Group type: EXPERIMENTAL
Intervention: ABT-229 1.25 mg
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: ABT-229 2.5 mg
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: ABT-229 5 mg
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: ABT-229 10 mg
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study: 9174180

Group type: EXPERIMENTAL
Intervention: Praziquantel (25 mg/kg) administered alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Praziquantel (25 mg/kg) administered with cimetidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison with other regimens
Number of subjects: 8
Study: 1606596

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 3.75 mg every 4 weeks (n = 9)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 7.5 mg every 4 weeks (n = 16)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 7.5 mg monthly injections (postmenopausal study, n = 15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (both doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (postmenopausal study)
Number of subjects: 40
Study: 3022036

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus chest irradiation (40 Gy between cycles 1 and 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus chest irradiation
Number of subjects: 50
Study: 31497981

Group type: EXPERIMENTAL
Intervention: Adaptive interventions (AIs) for promoting weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 29793868

Group type: EXPERIMENTAL
Intervention: 2 cmH2O of positive end-expiratory pressure (PEEP) for 1 hour
Number of subjects: 17

Group type: COMPARATOR
Intervention: 5 cmH2O of positive end-expiratory pressure (PEEP) for 1 hour
Number of subjects: 17
Study: 27197280

Group type: EXPERIMENTAL
Intervention: Alcohol consumption prior to breast cancer diagnosis
Number of subjects: 7835

Group type: EXPERIMENTAL
Intervention: Alcohol consumption prior to breast cancer diagnosis among ER(-) patients
Number of subjects: 7835

Group type: EXPERIMENTAL
Intervention: Alcohol consumption prior to breast cancer diagnosis among ER(+) patients
Number of subjects: 7835
Study: 24036024

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous cardiosphere-derived cells (CDCs) (12.5 to 25 × 10(6))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Routine-care control
Number of subjects: 17
Study: 22854401

Group type: EXPERIMENTAL
Intervention: Sucrose with whole blackcurrants (150 g served as purées) and 35 g added sucrose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sucrose with lingonberries (150 g served as purées) and 35 g added sucrose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sucrose with blackcurrant nectar (300 mL) and 35 g added sucrose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sucrose with lingonberry nectar (300 mL) and 35 g added sucrose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sucrose alone (35 g in 300 mL water)
Number of subjects: 20
Study: 20456744

Group type: EXPERIMENTAL
Intervention: CYP2D6*1/*1
Number of subjects: 40

Group type: COMPARATOR
Intervention: CYP2D6*2/*2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CYP2D6*2/*10
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10
Number of subjects: 40
Study: 18563541

Group type: EXPERIMENTAL
Intervention: Job placement and support program (PS group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Self-placement group (SP group)
Number of subjects: 66
Study: 17145527

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy (CT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional radiotherapy using delayed accelerated concomitant boost radiotherapy (CBRT) with concurrent chemotherapy (CT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IMRT with CT
Number of subjects: 112

Group type: COMPARATOR
Intervention: CBRT with CT
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 112

Group type: COMPARATOR
Intervention: CBRT
Number of subjects: 112
Study: 14505262

Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) and tibolone (2.5 mg per day) for 3-6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) with add-back therapy of norethindrone acetate (5 mg per day) from the first day of treatment
Number of subjects: 0
Study: 11225744

Group type: EXPERIMENTAL
Intervention: Oral continuous oestradiol (2.0 mg) + norethisterone acetate (1.0 mg) per day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Continuous transdermal oestrogen‐only (50 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy postmenopausal control women
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with metabolic syndrome
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with type 2 diabetes
Number of subjects: 46
Study: 9180492

Group type: EXPERIMENTAL
Intervention: Closed-system suction catheter (CSSC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open-system suction catheter (OSSC)
Number of subjects: 20
Study: 1588353

Group type: EXPERIMENTAL
Intervention: Age and psychosocial status
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Age and quality of life in married women who received segmental mastectomy
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Age, psychosocial status, and quality of life in married women who received segmental mastectomy
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Household income and age
Number of subjects: 229
Study: 3158260

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Short-term hypoxia
Number of subjects: 12
Study: 31255574

Group type: EXPERIMENTAL
Intervention: MDCK-derived H5N1 alum-adjuvanted vaccine (0.5 mL, 7.5, 15, or 30 μg of hemagglutinin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MDCK-derived H5N1 alum-adjuvanted vaccine (30 μg HA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MDCK-derived H5N1 alum-adjuvanted vaccine
Number of subjects: 36
Study: 28389097

Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-10 (3+0 schedule)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-30 (3+0 schedule)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-30 (2+1 schedule)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 1200
Study: 25702876

Group type: COMPARATOR
Intervention: Short-term androgen deprivation (4 months) with high-dose radiotherapy (76-82 Gy)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (24 months) with high-dose radiotherapy (76-82 Gy)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (24 months)
Number of subjects: 355
Study: 23800573

Group type: EXPERIMENTAL
Intervention: Citalopram 20mg once daily (n=38)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 48